EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieOpen Access · CC BY 4.0

Efficacy and Safety of 5-Aminolevulinic Acid Combined with Iron on Skeletal Muscle Mass Index and Physical Performance of Patients with Sarcopenia: A Multicenter, Double-Blinded, Randomized-Controlled Trial (ALADDIN Study)

Yoshifumi Tamura iD, Hideyoshi Kaga iD, Yasuko Abe, Hidenori Yoshii, Hiroaki Seino, Toru Hiyoshi, Nobuichi Kuribayashi, Ikuo Inoue, Hirotaka Watada

Nutrients · 24.06.2023 · 15 (13) · 2866

DOI: 10.3390/nu15132866 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Nutrients, online erschienen am 24.06.2023. Verfasst von Yoshifumi Tamura und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Sports Medicine and Sportology, Graduate School of Medicine, Juntendo University, 2-1-1 Hongo, Bunkyo-ku, Tokyo 113-8421, Japan. Hauptthemen laut MEDLINE: Sarcopenia. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: SBI Pharmaceuticals (Japan), SBI Pharmaceuticals Co., Ltd., EviPRO Co., Ltd..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Sarcopenia is a geriatric syndrome characterized by decreased physical performance, muscle mass, and strength. Since the intake of 5-aminolevulinic acid (ALA) with iron can increase muscle mass and mitochondria in mice and elevate physical exercise performance in humans, the beneficial effects of ALA in patients with sarcopenia are expected, but this remains unexplored in the literature. This study aimed to assess the efficacy and dose dependency of ALA combined with iron in sarcopenia by measuring skeletal muscle mass index (SMI). Subjects with sarcopenia were enrolled and randomized into the ALA and sodium ferrous citrate (SFC) intake groups (ALA50/SFC29, ALA100/SFC29, ALA150/SFC29, ALA 100/SFC57, and ALA0/SFC29 placebo) and ingested the assigned study food for 12 weeks. The primary endpoint, the change in SMI from baseline to week 12, did not differ significantly between the groups. Hand grip significantly increased or tended to increase from baseline after 12 weeks with all doses of ALA or SFC compared with the placebo group. No consistent changes were observed in the other endpoints, including calf circumference, physical function, or quality of life (QOL). Although this study suggests safe administration and the possibility of ALA improving hand grip strength in patients with sarcopenia, further investigation is required.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SarcopeniaHumansAnimalsMiceAgedAminolevulinic AcidQuality of LifeHand StrengthIronMuscle, SkeletalMuscle StrengthFerrous CompoundsCitric Acid

Stichwörter der Autor:innen

5-aminolevulinic acidhand gripironsarcopeniaskeletal muscle mass indexsodium ferrous citrate

Substanzen

Aminolevulinic AcidIronferrous citrateFerrous CompoundsCitric Acid

Autor:innen und Institutionen

  • Department of Sports Medicine and Sportology, Graduate School of Medicine, Juntendo University, 2-1-1 Hongo, Bunkyo-ku, Tokyo 113-8421, Japan.
  • Sportology Center, Juntendo University Graduate School of Medicine, Tokyo 113-8421, Japan.
  • Department of Metabolism and Endocrinology, Graduate School of Medicine, Juntendo University, 2-1-1 Hongo, Bunkyo-ku, Tokyo 113-8421, Japan.
  • Faculty of International Liberal Arts, Juntendo University, 2-1-1 Hongo, Bunkyo-ku, Tokyo 113-8421, Japan.
  • Department of Internal Medicine, Yokufukai Hospital, Social Welfare Foundation, Tokyo 168-0071, Japan.
  • Department of Insured Medical Care Management, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo 113-8519, Japan.

ORCID-Profile: Yoshifumi Tamura, Hideyoshi Kaga

Förderung

  • SBI Pharmaceuticals (Japan)
  • SBI Pharmaceuticals Co., Ltd.
  • EviPRO Co., Ltd.

Zitieren

APA

Tamura, Y., Kaga, H., Abe, Y., Yoshii, H., Seino, H., Hiyoshi, T., Kuribayashi, N., Inoue, I., & Watada, H. (2023). Efficacy and Safety of 5-Aminolevulinic Acid Combined with Iron on Skeletal Muscle Mass Index and Physical Performance of Patients with Sarcopenia: A Multicenter, Double-Blinded, Randomized-Controlled Trial (ALADDIN Study). Nutrients, 15(13), 2866. https://doi.org/10.3390/nu15132866

Vancouver

Tamura Y, Kaga H, Abe Y, Yoshii H, Seino H, Hiyoshi T, et al. Efficacy and Safety of 5-Aminolevulinic Acid Combined with Iron on Skeletal Muscle Mass Index and Physical Performance of Patients with Sarcopenia: A Multicenter, Double-Blinded, Randomized-Controlled Trial (ALADDIN Study). Nutrients. 2023;15(13):2866. doi:10.3390/nu15132866

BibTeX
@article{Tamura2023,
  author = {Tamura, Yoshifumi and Kaga, Hideyoshi and Abe, Yasuko and Yoshii, Hidenori and Seino, Hiroaki and Hiyoshi, Toru and Kuribayashi, Nobuichi and Inoue, Ikuo and Watada, Hirotaka},
  title = {Efficacy and Safety of 5-Aminolevulinic Acid Combined with Iron on Skeletal Muscle Mass Index and Physical Performance of Patients with Sarcopenia: A Multicenter, Double-Blinded, Randomized-Controlled Trial (ALADDIN Study)},
  journal = {Nutrients},
  year = {2023},
  volume = {15},
  number = {13},
  pages = {2866},
  doi = {10.3390/nu15132866}
}
Kostenlos starten →